

August 4, 2017

To,

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers
Dalal Street
Mumbai 400 001

Symbol: RPGLIFE

Scrip code: 532983

Dear Sir/Madam,

Sub: Outcome of Board Meeting

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform that the Board of Directors of the Company has, at its meeting held today i.e. on Friday, August 4, 2017 inter alia considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2017 along with Limited Review Report of the Statutory Auditors thereon.

Further, in terms of Regulation 33 of the Listing Regulations, we are enclosing herewith Unaudited Financial Results of the Company for the quarter ended June 30, 2017 alongwith Limited Review Report thereon issued by the Statutory Auditors of the Company.

The Board Meeting commenced at 12.00 noon and was concluded at 3.15 p.m.

The above information is for your information and records.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited


Rajesh Shirambekar
Head - Legal & Company Secretary



Encl: As above

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Review Report

To the Board of Directors of RPG Life Sciences Limited

We have reviewed the accompanying Statement of Unaudited Financial Results of RPG Life Sciences Limited ('the Company') for the quarter ended 30 June 2017 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015. The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 4 August 2017. Our responsibility is to issue a report on the Statement based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The unaudited financial results for the quarter ended 30 June 2016 included in the Statement, are based on the previously issued results of the Company prepared in accordance with the Accounting Standards as per Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 ("previous GAAP"). Those unaudited financial results prepared under previous GAAP were reviewed by the predecessor auditors, whose review report dated 27 July 2016 expressed an unmodified conclusion on those unaudited financial results. Management has adjusted those unaudited financial results for the differences in the accounting principles adopted by the Company on transition to Indian Accounting Standards ('Ind AS') and presented a reconciliation for the same, which have been approved by the Company's Board of Directors but have not been subjected to review.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 5 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP
Chartered Accountants

Firm's Registration No: 101248W/W - 100022



Bhavesh Dhupelia
Partner

Membership No: 042070

Mumbai
4 August 2017

(Rs. in Lakhs)		
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2017		
Particulars	3 months ended	
	30-06-2017	30-06-2016 (Refer note 2)
	Unaudited	
1 Revenue from Operations	7,851	8,259
2 Other Income	9	18
3 Total Income	7,860	8,277
4 Expenses		
(a) Cost of Materials Consumed	1,543	1,861
(b) Purchases of Stock-in-Trade	1,006	1,786
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(179)	(720)
(d) Excise Duty Paid	234	312
(e) Employee Benefits Expense	2,042	1,687
(f) Finance Costs	96	40
(g) Depreciation and Amortisation Expense	348	224
(h) Other Expenses	2,723	2,285
Total Expenses	7,813	7,475
5 Profit before tax from continuing operations	47	802
6 Income tax expenses		
a. Current Tax	10	213
b. Deferred Tax	(6)	(213)
7 Profit from continuing operations	43	802
8 Profit from discontinued operations before tax	-	147
9 Tax expenses of discontinued operations	-	-
10 Profit from discontinued operations	-	147
11 Profit for the period	43	949
12 Other Comprehensive Income		
(i) Items that will not be reclassified to Profit or Loss	(23)	(23)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	-	-
Other Comprehensive Income Net of Tax	(23)	(23)
13 Total Comprehensive Income for the period	20	926
14 Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323
15 Earnings per Share form discontinued operations (of Rs. 8 each) (not annualised):		
(a) Basic	-	0.89
(b) Diluted	-	0.89
Earnings per Share form continuing operations (of Rs. 8 each) (not annualised):		
(a) Basic	0.26	4.85
(b) Diluted	0.26	4.85

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 4, 2017. The Statutory Auditors of the Company have conducted a 'Limited Review' of the above Unaudited Financial Results for the quarter ended June 30, 2017.



Handwritten signature/initials



- On April 1, 2017 the Company has adopted the Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with effect from April 1, 2016. Accordingly, the financial results for the quarter ended June 30, 2017 have been prepared in accordance with Ind AS and other accounting principles generally accepted in India and the results for the comparative quarter ended June 30, 2016 have been restated in accordance with Ind AS. The financial results for the quarter ended June 30, 2016 have not been reviewed or audited by the auditors and are compiled by the management after exercising necessary due diligence to ensure that these give a true and fair view of the Company's affairs.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- Reconciliation of results between previous reported (referred to previous GAAP) and Ind AS for the quarter ended June 30, 2016 is presented as below:

		Rs. in Lakhs
Profit for quarter ended June 30, 2016 as per previous GAAP		987
Re-measurement of revenue	(a)	(61)
Re-measurement of Employee Benefit Net of tax	(b)	23
Other Comprehensive Income Net of Tax		949
Re-measurement of Employee Benefit Net of tax		(23)
Total Comprehensive Income for the period		926

Profit reconciliation Notes


- Provision for sales return has been made under Ind AS as per past trend of sales return to sales.
 - The re-measurement cost arising primarily due to changes in actuarial assumptions have been recognised in Other Comprehensive Income under Ind AS as compared to Statement of Profit or Loss under Previous GAAP.
- In the corresponding quarter ended June 30, 2016, pursuant to the approval of the Board of Directors at their meeting held on May 26, 2016, the Company had entered into a Business Transfer Agreement dated May 26, 2016 with Intas Pharmaceuticals Limited for sale of its Biotech Business Unit, as a going concern on a slump sale basis. The same has been considered as a discontinuing operation in June 2016, in accordance with Ind AS - 105 - "Non-current Assets held for sale and Discontinued Operations" and the requisite information for Biotech Business Unit has been furnished hereunder:

Particulars	(Rs. in Lakhs)	
	30-06-2017	30-06-2016
	Unaudited	
a) Revenue from Operations	-	661
b) Direct Expenses	-	514
c) Profit from ordinary activities before tax	-	147
d) Tax Expense (net off MAT Credit Entitlement)	-	-
e) Net Profit	-	147

- There are no exceptional items.
- The statement does not include Ind AS compliant results for the preceding quarter and previous year ended March 31, 2017 as the same is not mandatory as per SEBI's circular dated July 5, 2016.



For RPG Life Sciences Limited



CT. Renganathan
 Managing Director
 DIN - 02158397
 Mumbai, August 4, 2017

